Tranquility Partners LLC Sells 476 Shares of Zoetis Inc. (NYSE:ZTS)

Tranquility Partners LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 5.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,645 shares of the company’s stock after selling 476 shares during the period. Tranquility Partners LLC’s holdings in Zoetis were worth $1,246,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ZTS. AMF Tjanstepension AB raised its stake in shares of Zoetis by 23.4% in the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after acquiring an additional 20,001 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Zoetis by 4,582.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock valued at $320,000 after acquiring an additional 1,604 shares in the last quarter. CX Institutional raised its stake in shares of Zoetis by 6.3% in the 3rd quarter. CX Institutional now owns 8,142 shares of the company’s stock valued at $1,591,000 after acquiring an additional 482 shares in the last quarter. Creative Planning raised its stake in shares of Zoetis by 8.6% in the 3rd quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after acquiring an additional 7,170 shares in the last quarter. Finally, 626 Financial LLC bought a new position in Zoetis in the 3rd quarter worth approximately $212,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $173.99 on Thursday. The stock’s fifty day simple moving average is $169.11 and its 200 day simple moving average is $179.11. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a market cap of $78.50 billion, a price-to-earnings ratio of 32.70, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.15%. Zoetis’s payout ratio is 37.59%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent analyst reports. Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley dropped their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.